{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:06:03Z","timestamp":1747368363975,"version":"3.40.5"},"reference-count":35,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Background: Immunoglobulin A nephropathy (IgAN) is a rare disease poorly described in real-world settings. Thisobservational retrospective study aimed to assess the direct healthcare burden of new IgAN patients on the ItalianNational Healthcare Service (SSN).Methods: From the Fondazione Ricerca e Salute\u2019s database (administrative healthcare data of ~5.5 millioninhabitants\/year), inpatients with new potential in-hospital biopsy-verified IgAN from 2016 to 2019 were identified.Dispensations of IgAN-recommended and other drugs, kidney replacement therapies (KRT), hospitaland emergency department (ED) admissions, local outpatient specialist care, and related direct costs wereassessed throughout a 3-year follow-up.Results: New IgAN patients (n = 292) were identified (incidence\/year: 1.25\/100 000 inhabitants); 64% of patientswere male; the median age was 41 (27; 57) years. Annual consumption of most healthcare resources decreasedfrom Year 1 to 3: from 90% to 84% of patients received \u22651 IgAN-recommended drug; from 100% (due to selectioncriteria) to 15% of patients underwent overnight hospitalizations; from 8% to 3% patients underwent dayhospitalizations; from 31% to 21% patients underwent \u22651 ED access; from 87% to 85% patients received local outpatient specialist services. Of all patients, 2\u20134% were treated with KRT, and ~91% received other drugs. The percapita mean total annual cost was \u20ac7441 in Year 1 (hospitalizations accounting for 73% due to selection criteria),\u20ac3497 in Year 2, and \u20ac3243 in Year 3 (drugs accounting for 51%, mostly attributable to other drugs).Conclusion: This real-world study shows a substantial direct healthcare burden for new IgAN patients arising fromIgAN-specific care and comorbidities.<\/jats:p>","DOI":"10.33393\/grhta.2025.3397","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:35:53Z","timestamp":1747312553000},"page":"130-140","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare of patients with immunoglobulin A  nephropathy through a retrospective observational  study of Italian administrative data"],"prefix":"10.33393","volume":"12","author":[{"given":"Luigi","family":"Biancone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3168-6856","authenticated-orcid":false,"given":"Letizia","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-8110","authenticated-orcid":false,"given":"Giulia","family":"Ronconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-2855","authenticated-orcid":false,"given":"Silvia","family":"Calabria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Dell'Anno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-8961","authenticated-orcid":false,"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Addesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nello","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"16567","doi-asserted-by":"crossref","unstructured":"Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45. https:\/\/doi.org\/10.36469\/jheor.2021.26129 PMID:34692885","DOI":"10.36469\/jheor.2021.26129"},{"key":"16568","doi-asserted-by":"crossref","unstructured":"Lee M, Suzuki H, Nihei Y, et al. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023;16(suppl 2):ii1-ii8. https:\/\/doi.org\/10.1093\/ckj\/sfad199 PMID:38053973","DOI":"10.1093\/ckj\/sfad199"},{"key":"16569","doi-asserted-by":"crossref","unstructured":"Willey CJ, Coppo R, Schaefer F, et al. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38(10):2340-2349. https:\/\/doi.org\/10.1093\/ndt\/gfad082 PMID:37156519","DOI":"10.1093\/ndt\/gfad082"},{"key":"16570","doi-asserted-by":"crossref","unstructured":"Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753-779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015 PMID:34556300","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"16571","doi-asserted-by":"crossref","unstructured":"Zaza G, Bernich P, Lupo A. Incidence of primary glomerulonephritis in a large Northeastern Italian area: a 13-year renal biopsy study. Nephrol Dial Transplant. 2013;28(2):367-372. https:\/\/doi.org\/10.1093\/ndt\/gfs437 PMID:23223218","DOI":"10.1093\/ndt\/gfs437"},{"key":"16572","doi-asserted-by":"crossref","unstructured":"Cambier A, Rabant M, El Karoui K, et al. Clinical and histological differences between adults and children in new onset IgA nephropathy. Pediatr Nephrol. 2020;35(10):1897-1905. https:\/\/doi.org\/10.1007\/s00467-020-04614-3 PMID:32444925","DOI":"10.1007\/s00467-020-04614-3"},{"key":"16573","doi-asserted-by":"crossref","unstructured":"Wong K, Pitcher D, Braddon F, et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024;403(10433):1279-1289. https:\/\/doi.org\/10.1016\/S0140-6736(23)02843-X PMID:38492578","DOI":"10.1016\/S0140-6736(23)02843-X"},{"key":"16574","doi-asserted-by":"crossref","unstructured":"Caster DJ, Abner CW, Walker PD, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8(9):1792-1800. https:\/\/doi.org\/10.1016\/j.ekir.2023.06.016 PMID:37705898","DOI":"10.1016\/j.ekir.2023.06.016"},{"key":"16575","doi-asserted-by":"crossref","unstructured":"\u0218tefan G, Zugravu A, Stancu S. Mortality in IgA nephropathy: a long-term follow-up of an Eastern European Cohort. Medicina (Kaunas). 2024;60(2):247. https:\/\/doi.org\/10.3390\/medicina60020247 PMID:38399535","DOI":"10.3390\/medicina60020247"},{"key":"16576","doi-asserted-by":"crossref","unstructured":"Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. https:\/\/doi.org\/10.2215\/CJN.0000000000000135 PMID:37055195","DOI":"10.2215\/CJN.0000000000000135"},{"key":"16577","doi-asserted-by":"crossref","unstructured":"Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3(3):CD003965. PMID:32162319","DOI":"10.1002\/14651858.CD003965.pub3"},{"key":"16578","doi-asserted-by":"crossref","unstructured":"Tunnicliffe DJ, Reid S, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024;2(2):CD003962. PMID:38299639","DOI":"10.1002\/14651858.CD003962.pub3"},{"key":"16579","doi-asserted-by":"crossref","unstructured":"Di Leo V, Annese F, Papadia F, et al. Refractory IgA nephropathy: a challenge for future nephrologists. Medicina (Kaunas). 2024;60(2):274. https:\/\/doi.org\/10.3390\/medicina60020274 PMID:38399561","DOI":"10.3390\/medicina60020274"},{"key":"16580","unstructured":"Agenzia Italiana del Farmaco. DETERMINA 31 luglio 2024. Classificazione, ai sensi dell'articolo 12, comma 5, della legge 8 novembre 2012, n. 189, del medicinale per uso umano, a base di sparsentan, \u00abFilspari\u00bb. (Determina n. 409\/2024). (24A04219) (GU Serie Generale n.190 del 14-08-2024). 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2024-08-14&atto.codiceRedazionale=24A04219&elenco30giorni=true (Accessed November 2024)"},{"key":"16581","unstructured":"Agenzia Italiana del Farmaco. DETERMINA 11 ottobre 2024. Classificazione, ai sensi dell'articolo 12, comma 5, della legge 8 novembre 2012, n. 189, del medicinale per uso umano, a base di budesonide, \u00abKinpeygo\u00bb. (Determina n. 576\/2024). (24A05512) (GU Serie Generale n.248 del 22-10-2024). 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2024-10-22&atto.codiceRedazionale=24A05512&elenco30giorni=false"},{"key":"16582","unstructured":"Italian Medicines Agency. Compassionate use programmes 2024. Online https:\/\/www.aifa.gov.it\/en\/farmaci-a-uso-compassionevole. (Accessed November 2024)"},{"key":"16583","doi-asserted-by":"crossref","unstructured":"Lerma EV, Bensink ME, Thakker KM, et al. Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with IgA nephropathy in the United States: A Retrospective Analysis. Kidney Med. 2023;5(9):100693. https:\/\/doi.org\/10.1016\/j.xkme.2023.100693 PMID:37637862","DOI":"10.1016\/j.xkme.2023.100693"},{"key":"16584","doi-asserted-by":"crossref","unstructured":"Jhaveri KD, Bensink ME, Bunke M, et al. Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis. PharmacoEconom Open. 2023;7(5):709-722. https:\/\/doi.org\/10.1007\/s41669-023-00415-0 PMID:37103750","DOI":"10.1007\/s41669-023-00415-0"},{"key":"16585","unstructured":"ISTAT. Anni 2002-2018. Ricostruzione della popolazione residente, per sesso, et\u00e0 e Comune; 2021. Online https:\/\/www.istat.it. (Accessed November 2024)"},{"key":"16586","unstructured":"European Parliament and Council of the European Union. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. 2014 https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32014R0536 (Accessed November 2024)"},{"key":"16587","unstructured":"European Parliament and Council of the European Union. Regulation (EU) 2016\/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation). 2016. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32016R0679 (Accessed November 2024)"},{"key":"16588","unstructured":"Garante per la protezione dei dati personali [Authority for the protection of personal data]. Provvedimento recante le prescrizioni relative al trattamento di categorie particolari di dati, ai sensi dell\u2019art. 21, comma 1 del d.lgs. 10 agosto 2018, n. 101 [Provision for the processing of particular categories of data]. Gazzetta Ufficiale [Official Gazette] Serie Generale n.176 del 29 luglio 2019. https:\/\/www.garanteprivacy.it\/home\/docweb\/-\/docweb-display\/docweb\/9124510 (Accessed November 2024)"},{"key":"16589","unstructured":"Italian Ministry of Health. Decreto 30 novembre 2021. Misure volte a facilitare e sostenere la realizzazione degli studi clinici di medicinali senza scopo di lucro e degli studi osservazionali e a disciplinare la cessione di dati e risultati di sperimentazioni senza scopo di lucro a fini registrativi, ai sensi dell'art. 1, comma 1, lettera c), del decreto legislativo 14 maggio 2019, n. 52. (22A01189). Gazzetta Ufficiale [Official Gazette] Serie Generale n. 42 del 19 febbraio 2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/02\/19\/22A01189\/sg (Accessed November 2024)"},{"key":"16590","unstructured":"Ministero del Lavoro della Salute e delle Politiche Sociali. Nomenclatore prestazioni di assistenza specialistica ambulatoriale. Allegato 4. DPCM 12 gennaio 2017. 2017. http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=18\/03\/2017&redaz=17A02015&artp=4&art=1&subart=1&subart1=10&vers=1&prog=001 (Accessed November 2024)"},{"key":"16591","doi-asserted-by":"crossref","unstructured":"Knoop T, Vikse BE, Svarstad E, et al. Mortality in patients with IgA nephropathy. Am J Kidney Dis. 2013;62(5):883-890. https:\/\/doi.org\/10.1053\/j.ajkd.2013.04.019 PMID:23796906","DOI":"10.1053\/j.ajkd.2013.04.019"},{"key":"16592","doi-asserted-by":"crossref","unstructured":"Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA nephropathy: a nationwide population-based cohort study. J Am Soc Nephrol. 2019;30(5):866-876. https:\/\/doi.org\/10.1681\/ASN.2018101017 PMID:30971457","DOI":"10.1681\/ASN.2018101017"},{"key":"16593","doi-asserted-by":"crossref","unstructured":"Cattran DC, Floege J, Coppo R. Evaluating progression risk in patients with immunoglobulin A nephropathy. Kidney Int Rep. 2023;8(12):2515-2528. https:\/\/doi.org\/10.1016\/j.ekir.2023.09.020 PMID:38106572","DOI":"10.1016\/j.ekir.2023.09.020"},{"key":"16594","doi-asserted-by":"crossref","unstructured":"Esposito S, Noviello S, Boccazzi A, et al. Management of upper respiratory tract infections in primary care in Italy: a national survey. Int J Antimicrob Agents. 2001;17(3):189-194. https:\/\/doi.org\/10.1016\/S0924-8579(00)00335-6 PMID:11282263","DOI":"10.1016\/S0924-8579(00)00335-6"},{"key":"16595","doi-asserted-by":"crossref","unstructured":"Infante B, Rossini M, Di Lorenzo A, et al. Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy. Clin Kidney J. 2020;13(5):758-767. https:\/\/doi.org\/10.1093\/ckj\/sfaa060 PMID:33123355","DOI":"10.1093\/ckj\/sfaa060"},{"key":"16596","doi-asserted-by":"crossref","unstructured":"Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults-treatment standard. Nephrol Dial Transplant. 2023;38(11):2464-2473. https:\/\/doi.org\/10.1093\/ndt\/gfad146 PMID:37418237","DOI":"10.1093\/ndt\/gfad146"},{"key":"16597","doi-asserted-by":"crossref","unstructured":"Selvaskandan H, Barratt J, Cheung CK. Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep. 2023;9(2):203-213. https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026 PMID:38344739","DOI":"10.1016\/j.ekir.2023.11.026"},{"key":"16598","doi-asserted-by":"crossref","unstructured":"Barbour S, Lo C, Espino-Hernandez G, et al. The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice. Nephrol Dial Transplant. 2018;33(4):626-634. https:\/\/doi.org\/10.1093\/ndt\/gfx185 PMID:29106654","DOI":"10.1093\/ndt\/gfx185"},{"key":"16599","doi-asserted-by":"crossref","unstructured":"Trifir\u00f2 G, Gini R, Barone-Adesi F, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347-363. https:\/\/doi.org\/10.1007\/s40264-018-0732-5 PMID:30269245","DOI":"10.1007\/s40264-018-0732-5"},{"key":"16600","unstructured":"Canada's Drug Agency. A Roadmap for Patient and Disease Registries: Linking Health Data to Enhance Rare Disease Decision-Making 2024. Online https:\/\/www.cda-amc.ca\/news\/roadmap-patient-and-disease-registries-linking-health-data-enhance-rare-disease-decision (Accessed November 2024)"},{"key":"16601","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Valc\u00e1rcel-Nazco C, et al. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. 2021;16(1):178. https:\/\/doi.org\/10.1186\/s13023-021-01815-3 PMID:33849613","DOI":"10.1186\/s13023-021-01815-3"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3397\/4022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3397\/4023","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3397\/4022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:36:13Z","timestamp":1747312573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2025.3397","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}